Material Agreement Form 8 K

Item 1.01. Entry into a material definitive agreement

On September 02, 2024, the International Institute of Great Health, Inc. (the "Company"), a wholly owned subsidiary of America Great Health, entered into a Technology Contract for Commissioned Development (the "Contract") with Yunan Yunchi Xiai Trading Co. Ltd., a Chinese company ("Yunchi"). Under the Contract, Yunchi has engaged the Company to provide specialized technical development for its Ganoderma lucidum ionic peptide project and will compensate the Company for these services. The development involves the Company's proprietary, patented protein skin surface ion modification, transformation technology, which will be applied to Yunchi's existing Ganoderma lucidum raw materials. This process will not only preserve the original properties of the materials but also add the ability to inhibit the growth of cancer cells in vitro.

According to the Contract, the technology development will take place in a laboratory in the United States, while the experimental base will be in China. The development period is set for three (3) months.